EXOZ on Nasdaq

EXOZYMES INC.

American biological products company that raised $12,000 in 2024 (SEC Form D). Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with BioCardia, Inc., AIM ImmunoTech Inc. or Inmune Bio, Inc., or pick any stock.

  • TickerEXOZ on Nasdaq1
  • IndustryBiological Products, (No Diagnostic Substances)1
  • HeadquartersMonrovia, California1
  • Incorporated inNV2
  • Business address750 Royal Oaks Dr, Monrovia, Ca 910162
  • Filer category, Emerging growth company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

Inc. has also received grants from two non-government sources. One of the grants was from the Gates Foundation for work on terpene synthesis.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

-2563.5%Operating margin4
-2909.1%Net margin4
-$1.5MFree cash flow4

Where the money goes

Where each dollar of revenue went, fiscal 2023

  • Research and development93¢$527.5K
  • Income tax7¢$42.3K

Out of $70.1K in revenue.45 The company lost money this year.

Financial statements

Every line of the income statement as filed: the last 3 fiscal years, latest first.5

Period ending2025-12-312024-12-312023-12-31
Compensation$3.6M$2.5M
Professional fees$1.4M$1.2M
Information technology$96.0K$38.7K
General and administrative-other$836.1K$329.7K
Total general and administrative costs$6.0M$4.1M
Research and development costs$3.7M$1.9M
Total operating costs$9.7M$5.9M
Net operating loss-$9.7M-$5.9M
Interest income, net$363.8K$77.6K
Other income/(expense)$88.7K-$6.8K
Change in fair value of SAFE-$8
Loss before income taxes-$9.3M-$5.9M
Income tax benefit$105.2K-$42.3K
Net loss-$9.2M-$5.9M
Net loss per common share - basic-$1.09-$0.89
Net loss per common share - diluted-$1.09-$0.89
Weighted average of common shares outstanding - basic8.4M shares6.6M shares
Weighted average of common shares outstanding - diluted8.4M shares6.6M shares

Compare EXOZYMES INC. with another company

Leadership

Who has led EXOZYMES INC., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Michael Heltzen2024–now

Chair

  1. Mohammad Hayat2024

President

  1. Mohammad Hayat2024
2025
Board members and other officers (9)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • DirectorJames Lalonde named Nov 19, 202419

Former names

  • Invizyne Technologies IncFeb 9, 2024 to Jan 21, 20252

Timeline

  1. Nov 18, 2024New chief executive Michael Heltzen becomes CEO8

Filings

120 filings to the SEC since October 2021: 2 annual reports, 6 quarterly reports, 22 major events, 32 insider forms, 4 large holders, 1 private raises, 53 other. The latest 20:

  1. Oct 9, 20268-K EDGAR
  2. Sep 28, 2026DEFA14A EDGAR
  3. Sep 28, 2026DEF 14A EDGAR
  4. Sep 18, 20268-K EDGAR
  5. Sep 17, 20264 EDGAR
  6. Sep 2, 20264 EDGAR
  7. Aug 25, 20264 EDGAR
  8. Aug 25, 20264 EDGAR
  9. Aug 13, 202610-Q EDGAR
  10. Jul 1, 20268-K EDGAR
  11. Jun 30, 2026424B5 EDGAR
  12. Jun 26, 20268-K EDGAR
  13. Jun 17, 20268-K EDGAR
  14. Jun 8, 20268-K EDGAR
  15. Jun 8, 2026424B5 EDGAR
  16. Jun 4, 2026424B5 EDGAR
  17. May 29, 2026424B5 EDGAR
  18. May 14, 202610-Q EDGAR
  19. May 7, 20268-K EDGAR
  20. Apr 10, 20268-K EDGAR

The 120 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

8 open-market trades by officers, directors and large owners since October 2021: 6 buys and 2 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 26, 2026Heltzen MichaelChief Executive OfficerBuy505$7.48$3.8KForm 4
Aug 25, 2026Heltzen MichaelChief Executive OfficerBuy350$7.51$2.6KForm 4
Apr 9, 2026Korman Tyler PazChief Scientific OfficerSale750$10.53$7.9KForm 4
Apr 8, 2026Korman Tyler PazChief Scientific OfficerSale750$10.04$7.5KForm 4
Jul 2, 2025Heltzen MichaelChief Executive OfficerBuy1,040$10.22$10.6KForm 4
Jan 17, 2025Heltzen MichaelChief Executive OfficerBuy1,767$10.78$19.0KForm 4
Jan 16, 2025Heltzen MichaelChief Executive OfficerBuy121$10.72$1.3KForm 4
Nov 15, 2024Heltzen MichaelChief Executive OfficerBuy1,984$11.10$22.0KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Nov 14, 2024Raised $11,718 in a private offering of securities Form D: 2 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Vanguard Capital Management LLC54,985$463.5K0.0%+32,795
Davidson Kahn Capital Management, LLC25,000$210.8K0.1%New
Geode Capital Management, LLC23,406$197.3K0.0%+1,515
BlackRock, Inc.9,610$81.0K0.0%+2,813
Vanguard Fiduciary Trust Co9,426$79.5K0.0%No change
Morgan Stanley1,250$10.5K0.0%No change
Tower Research Capital LLC (TRC)349$2.9K0.0%−968
UBS Group AG203$1.7K0.0%+179
Barclays PLC75$6320.0%New

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23